13,82
10-января-25 12:26:10
15 мин. задержка
Акции
-0,44
-3,05%
Сегодняшний диапазон
13,42 - 14,20
ISIN
N/A
Источник
NASDAQ
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
10 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
08 янв 2025 08:00:01 Источник Nasdaq GlobeNewswire